Vaishali Pharma announced its acquisition of a majority stake in Kesar Pharma Limited. Abans Financial Services Limited served as the exclusive financial advisor for this transaction.

Founded in 2008, Vaishali Pharma Limited specializes in pharmaceutical APIs, formulations, surgical products, and nutraceuticals. It became public in 2017 and have international presence with headquartered situated in Mumbai.

Kesar Pharma Limited, operating WHO-GMP certified facilities, specializes in manufacturing, contract manufacturing, and private label production of diverse pharmaceutical formulations, including tablets, syrup and ointments.

The cash and stock deal combines Vaishali Pharma's market presence with Kesar Pharma's manufacturing expertise and R&D. With this acquisition, Vaishali Pharma gains a manufacturing facility that complies with WHO-GMP and other international regulatory guidelines. Leveraging Kesar's manufacturing and supply chain strengths alongside Vaishali's global reach, the merged entity is poised for accelerated growth in domestic and international markets.

Atul Vasani, Chairman of Vaishali Pharma, stated, "This acquisition marks a significant milestone for both companies. By joining forces with Kesar Pharma, we aim to maximize the utilization of its advanced manufacturing facilities while maintaining the highest industry standards. This strategic move will allow us to scale our operations, enhance our global reach, and continue delivering high-quality, affordable healthcare solutions. We are confident that this partnership will create long-term value for our stakeholders and help us achieve our ambitious growth targets.

Further, we extend our gratitude to Investment Banking team of Abans for their comprehensive support from deal conceptualization and structuring, bringing a unique value proposition and seamless execution of all facets of the transaction process resulting in this successful acquisition."

Nirbhay Vassa, Whole Time Director and CFO, Abans Financial Services Limited said, “Abans is pleased to announce the strategic acquisition of Kesar Pharma Limited by Vaishali Pharma Limited. This strategic acquisition brings together two organizations anchored in similar values. We remain excited about its future prospects, given a large global market opportunity. We wish the companies success in their continued quest to create sustainable value for all their stakeholders.”

Ketur Shah, Investment Banker at Abans Financial Services Limited added, “Abans was privileged to partner with Vaishali Pharma, supporting their acquisition, business strategy and growth needs. We are pleased to have guided them through the acquisition of a majority stake in Kesar Pharma Limited. We wish Vaishali and Kesar Pharma Limited continued success in their next phase of growth.”

This acquisition marks a pivotal moment for Vaishali Pharma and Kesar Pharma, strengthening their market position and unlocking new growth opportunities. The combined entity is poised to drive innovation, expand product offerings, and enhance operational efficiencies by integrating its expertise, resources, and global networks.

With a shared commitment to quality, compliance, and customer satisfaction, this strategic move reinforces its mission to deliver high-quality, affordable healthcare solutions worldwide. As Vaishali Pharma and Kesar Pharma move forward together, with Abans Financial Services playing a key advisory role, they remain dedicated to creating long-term value for stakeholders and advancing their presence in the pharmaceutical industry.